• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Overview
    • Open Positions
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Overview
    • Open Positions
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
18AugAugust 18, 2025

Effect of Vepdegestrant, a PROTAC Oestrogen Receptor Degrader, on Dabigatran and Rosuvastatin Pharmacokinetics in Healthy Participants

30MayMay 30, 2025

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

07MayMay 7, 2025

PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

02JanJanuary 2, 2025

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader

20NovNovember 20, 2024

Safety and Pharmacokinetics of Vepdegestrant in Japanese Patients with ER+ Advanced Breast Cancer: A Phase 1 Study

05NovNovember 5, 2024

Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer

19SepSeptember 19, 2024

New Therapies on the Horizon: Targeted Protein Degradation in Neuroscience

31JulJuly 31, 2024

VERITAC-2: A Phase III Study of Vepdegestrant, a PROTAC ER Degrader, Versus Fulvestrant in ER+/ HER2- Advanced Breast Cancer

31MayMay 31, 2024

Oral Estrogen Receptor PROTAC® Vepdegestrant (ARV-471) is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or P13K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

23MayMay 23, 2024

Systematic Literature Review of Real-World Evidence for Treatments in HR+/HER2- Second-line LABC/mBC After First-line Treatment with CDK4/6i

12Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2025 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE